{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T08:07:36Z","timestamp":1767514056377,"version":"3.48.0"},"reference-count":18,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2025,12,14]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>We report the case of a middle childhood boy diagnosed with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD), who was resistant to initial steroid pulse therapy and plasma exchange but achieved long-term remission following rituximab (RTX) treatment. Over a 4-year follow-up, the patient experienced no relapse, serum anti-MOG antibodies were undetectable and steroids were successfully tapered and discontinued. This case highlights the potential efficacy of RTX not only as a relapse-preventing agent but also as an acute-phase therapy in paediatric-onset MOGAD.<\/jats:p>","DOI":"10.1136\/bcr-2025-269514","type":"journal-article","created":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T08:05:12Z","timestamp":1767513912000},"page":"e269514","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Rituximab as acute rescue therapy for paediatric MOGAD refractory to standard treatment"],"prefix":"10.1136","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2491-9150","authenticated-orcid":false,"given":"Norifumi","family":"Yokoyama","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Gifu Municipal Hospital, Gifu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aki","family":"Kawase","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Gifu Municipal Hospital, Gifu, Japan"},{"name":"Department of Pediatrics, Gifu University, Gifu, Gifu Prefecture, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6571-5651","authenticated-orcid":false,"given":"Taichi","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Gifu Municipal Hospital, Gifu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikko","family":"Oshiro","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Gifu Municipal Hospital, Gifu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"key":"2026010400050492000_19.1.e269514.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2013.118"},{"key":"2026010400050492000_19.1.e269514.2","doi-asserted-by":"crossref","first-page":"1535571","DOI":"10.3389\/fimmu.2025.1535571","article-title":"Clinical characteristics and factors associated with recurrence and long-term prognosis in patients with MOGAD","volume":"16","author":"Sun","year":"2025","journal-title":"Front Immunol"},{"key":"2026010400050492000_19.1.e269514.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2022.577812"},{"key":"2026010400050492000_19.1.e269514.4","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(22)00431-8"},{"key":"2026010400050492000_19.1.e269514.5","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders","volume":"75","author":"L\u00f3pez-Chiriboga","year":"2018","journal-title":"JAMA Neurol"},{"key":"2026010400050492000_19.1.e269514.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2023.06.009"},{"key":"2026010400050492000_19.1.e269514.7","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx276"},{"key":"2026010400050492000_19.1.e269514.8","doi-asserted-by":"crossref","unstructured":"Cacciaguerra L , Morris P , Tobin WO , et al . Tumefactive Demyelination in MOG Ab\u2013Associated Disease, Multiple Sclerosis, and AQP-4-IgG\u2013Positive Neuromyelitis Optica Spectrum Disorder. Neurology 2023;100. doi:10.1212\/WNL.0000000000206820","DOI":"10.1212\/WNL.0000000000206820"},{"key":"2026010400050492000_19.1.e269514.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102191"},{"key":"2026010400050492000_19.1.e269514.10","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410350304"},{"key":"2026010400050492000_19.1.e269514.11","doi-asserted-by":"crossref","first-page":"105829","DOI":"10.1016\/j.msard.2024.105829","article-title":"Clinical practice guidelines for multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody-associated disease 2023 in Japan","volume":"90","author":"Niino","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"2026010400050492000_19.1.e269514.12","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001052","article-title":"International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis","volume":"8","author":"Nosadini","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2026010400050492000_19.1.e269514.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102251"},{"key":"2026010400050492000_19.1.e269514.14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1582789","article-title":"Case report on severe myelin oligodendrocyte glycoprotein antibody-associated disease relapse after ectopic pregnancy and laparoscopic medical abortion: relevance of peripheral inflammation for demyelinating disease activity","volume":"16","author":"Smertinaite","year":"2025","journal-title":"Front Immunol"},{"key":"2026010400050492000_19.1.e269514.15","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s10072-023-07189-7","article-title":"Tocilizumab treatment in MOGAD: a case report and literature review","volume":"45","author":"Schir\u00f2","year":"2024","journal-title":"Neurol Sci"},{"key":"2026010400050492000_19.1.e269514.16","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3934\/Neuroscience.2025008","article-title":"Interleukin-6 targeting antibodies for the treatment of Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD): A review of current literature","volume":"12","author":"Ganesh","year":"2025","journal-title":"AIMS Neurosci"},{"key":"2026010400050492000_19.1.e269514.17","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-025-13279-7","article-title":"Immunotherapies in neuromyelitis optica: Bayesian network meta-analysis","volume":"272","author":"John","year":"2025","journal-title":"J Neurol"},{"key":"2026010400050492000_19.1.e269514.18","first-page":"1238","article-title":"Rituximab-associated hypogammaglobulinemia and infection risk in children","volume":"147","author":"Labrosse","year":"2021","journal-title":"J Allergy Clin Immunol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2025-269514","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T08:05:13Z","timestamp":1767513913000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2025-269514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,3]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/bcr-2025-269514"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2025-269514","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}